|
|
Post by sportsrancho on Nov 23, 2016 15:11:57 GMT -5
I'm talking about people that already have the connections. ( Not reps with gifts ) IMO we need a different way of marketing Afrezza and MNKD should take advantage of these connections on a continuing basis. more than 50% of primary care physician doesn't want to see a pharma rep , and the rest 50% have a really good relation with a big pharma company (with plenty of gifts per year) .. how can a new rep of a new company have a good connections with an endo ?, you tell me .. (all the top reps are still with the big pharma, you can not get these reps easily, even if you can get them, you need to spend money crazily to get access to these endos , and Mannkind is just a very small pharma company and doesn't have enough money to give gifts to these endos . (I saw many doctors have gifts : tickets to sport events, restaurant Christmas gifts, wine bottle gifts, free flight tickets to conferences etc .. ) and they (the endos) have relations with these big pharmas for many years already . An individual pharma rep doesn't have this kind of power . Right! You made my point! Again, I'm not talking about reps. I'm talking about people that I know. That already have the connections. People in LA, SD, 3 or 4 people from other states. MNKD should use these people. IMO they should not be over looked or their connections taken lightly. |
|
|
|
Post by cjm18 on Nov 23, 2016 21:56:26 GMT -5
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Nov 23, 2016 22:58:19 GMT -5
You do know that article was written November 4 of "2015". Nevertheless, it is still worth looking at. And, I totally agree with you that Pediatric approval cannot come fast enough, and your other points.
|
|
|
|
Post by tingtongtung on Nov 24, 2016 4:34:48 GMT -5
"A product of any sort will not sell if there is no demand." The demand is not there because such a small percentage of the diabetic public know about it, and many that do, don't have the whole picture. Demand has to be created by mass, effective advertising. SNY could have done this, and may have done it but for the most unfortunate change in CEO. Don't think we have anywhere near the money to do it, and persuade people that they do NEED Afrezza. That's what clever ads do, right? Getting to the endos is fine, too, but I've look at the pressure that MNKD could generate by having a million or so diabetics say, "we want to try this stuff!" I can't imagine that in that case, you wouldn't get 20,000 new Rx over six months. Disclaimer: I haven't been able to imagine a whole lot lately that has come to pass. You are right! When a lot of patients start asking for a particular drug, the doctors are forced to at least try to do some research on that, if not start prescribing it immediately. But, the ad campaign must be a big and prolonged one. It can't be what MNKD doing now with ~40 sales people. It has to be on many channels constantly bombarding people. With tons of cord cutters, it should be on radio, Hulu, etc. too. It's easy to advocate DTC ads, but the turnaround time with DTC will be slow as well. It's very expensive, and result is not immediate. One Superbowl appearance is just not enough! I'm sure ad budget will be around 200-300 mm with at least 8-10 months for a decent brand buildup? This along with the normal Dr visits by sales people. So, it's an expensive strategy to go DTC route. May be that's why MNKD wants to do the cheaper route of directly educating Drs, and social media.. They can stretch the money for a longer time building traction slowly. It's hard with constraints with cash, and other resources. I'm frustrated with Afrezza sales, but I do understand constraints faced by MNKD. I hope social media route works really well for us. I had this video (Al Mann) book marked to watch when I had enough time: www.youtube.com/watch?v=muBuxTqxmQoHe talks about capital around 7.15 in the video.. How true is that!! I wish MNKD had another 2-3 hundred million now. Al was a very smart, almost grandfatherly(!) person. Sanofi shouldn't have screwed us.. |
|
|
|
Post by slugworth008 on Nov 25, 2016 0:04:10 GMT -5
I'm talking about people that already have the connections. ( Not reps with gifts ) IMO we need a different way of marketing Afrezza and MNKD should take advantage of these connections on a continuing basis. more than 50% of primary care physician doesn't want to see a pharma rep , and the rest 50% have a really good relation with a big pharma company (with plenty of gifts per year) .. how can a new rep of a new company have a good connections with an endo ?, you tell me .. (all the top reps are still with the big pharma, you can not get these reps easily, even if you can get them, you need to spend money crazily to get access to these endos , and Mannkind is just a very small pharma company and doesn't have enough money to give gifts to these endos . (I saw many doctors have gifts : tickets to sport events, restaurant Christmas gifts, wine bottle gifts, free flight tickets to conferences etc .. ) and they (the endos) have relations with these big pharmas for many years already . An individual pharma rep doesn't have this kind of power . Probably very true, however all the Afrezza Reps have to has to do is get a foot in the door - and DTC will help that tremendously in whatever form that takes. JMHO |
|
|
|
Post by kbrion77 on Nov 25, 2016 11:35:02 GMT -5
My little theory is that many current Afrezza prescribing doctors on the list are watching MNKD stock also. The financial situation of MNKD has made many of them hesitate to prescribe Afrezza to their patients. With the latest quarterly CC from MNKD, more will be encouraged to start prescribing Afrezza again. So I predict we can see >20% NRX improvement this Friday...
I have been wrong with MNKD stock for so many times already, hope this time I am right! 
Sorry but yet another prediction gone wrong. Don't worry the Thanksgiving excuse is already warming up for next week's numbers. |
|
|
|
Post by u1682002 on Nov 25, 2016 11:46:57 GMT -5
My little theory is that many current Afrezza prescribing doctors on the list are watching MNKD stock also. The financial situation of MNKD has made many of them hesitate to prescribe Afrezza to their patients. With the latest quarterly CC from MNKD, more will be encouraged to start prescribing Afrezza again. So I predict we can see >20% NRX improvement this Friday...
I have been wrong with MNKD stock for so many times already, hope this time I am right!
Sorry but yet another prediction gone wrong. Don't worry the Thanksgiving excuse is already warming up for next week's numbers. I was very wrong this time and no more gut feeling guessing from me again. Nevertheless buying another 5k again @ 0.56. |
|
|
|
Post by kbrion77 on Nov 25, 2016 11:59:52 GMT -5
Sorry but yet another prediction gone wrong. Don't worry the Thanksgiving excuse is already warming up for next week's numbers. I was very wrong this time and no more gut feeling guessing from me again. Nevertheless buying another 5k again @ 0.56. Everybody has been wrong, well outside of short sellers who have called this stock insanely perfect the last 2 years. |
|
|
|
Post by ilovekauai on Nov 25, 2016 12:11:32 GMT -5
Chirp, chirp...patience my little grasshoppers and don't let the jaybirds & ravens scare you; otherwise they will eat you! Our time will come. Remain resolute. Have a nice Holiday weekend all. Aloha.
|
|
